XVIVO Heart Box for Heart Transplant

This study is looking at a new way to preserve and transport donor hearts for transplantation using the XVIVO Heart Preservation System (XHPS). This system uses Non-Ischemic Heart Preservation (NIHP), which means the heart is kept without blood flow, to see if it's safe and effective for hearts that might not meet standard donation criteria. The goal is to see how many patients successfully receive a transplant and how many are still alive one year later. You could be eligible if you are 18 or older, are waiting for a heart transplant, and have signed a consent form. This is a continuation of a previous study to gather more information while the system is being reviewed for wider use.

Study design
This study is an interventional study with a planned enrollment of 60 participants. It is a continuation of a previous trial to gather additional data.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 30 days after transplantation to measure treatment success, and for 365 days (one year) to measure survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06895070

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Recruiting
NAAges 18+InterventionalTreatment
XVIVO Perfusion
~60 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The percentage of patient treatment success rate
Measured over 30 days post transplantation
+1 more outcome measured
Heart Transplant
Heart Failure
Transplant; Failure, Heart

NCT06895070

Where you'd take part

This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

  • Columbia University Medical Center/New York Presbyterian Hospital

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Duke University Medical Center

    Durham, North Carolinastudy coordinator listed

    Recruiting

  • Emory University Hospital

    Atlanta, Georgiastudy coordinator listed

    Recruiting

  • Northwestern Memorial Hospital

    Chicago, Illinoisstudy coordinator listed

    Recruiting

  • NYU Langone

    New York, New Yorkstudy coordinator listed

    Recruiting

  • Stanford University

    Stanford, Californiastudy coordinator listed

    Recruiting

  • UC San Diego Health

    La Jolla, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Sarah Lowe · STUDY_DIRECTOR · XVIVO Perfusion

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥50 years
LVEF 40% - 50% at time of provisional acceptance. (Refer to section 6.3.4 for definition of provisional acceptance).
Down-time ≥20 minutes
Hypertrophy septal thickness \>12 - ≤16mm
Angiographic luminal irregularities with no significant CAD OR 1) Donation after Circulatory Death (DCD)

Exclusion

Participant with calculated Panel Reactive Antibody (cPRA) greater than 50%
Participant undergoing any desensitization treatment (also with cPRA less than 50%)
Participant with a positive prospective crossmatch and/or a positive virtual cross match
  • The percentage of patient treatment success rate30 days post transplantation

    The percentage of patient treatment success rate at 30-days post transplantation. The treatment success is defined as freedom from treatment failure.

  • The percentage of patient survivalPost-operative Day 365.

    The percentage of patient survival at 365 days from the date of transplant. The long-term safety success is defined as survival.